Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May 6;7(1):150.
doi: 10.1038/s41392-022-01015-w.

Surrogate cytokine agonists: promising agents against COVID-19

Zemin Lin  1 , Jianping Zuo  2   3   4 , Shijun He  5   6
Affiliations
Comment

Surrogate cytokine agonists: promising agents against COVID-19

Zemin Lin et al. Signal Transduct Target Ther. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no competing interests.

Figures

Fig. 1
Fig. 1
The bispecific type-I interferon surrogate ligands exhibit antiviral and pro-inflammatory effects discriminately. Human IFN surrogates ligands induced decreased activation of pSTAT1 but equivalent activation of pSTAT2 and pSTAT3 compared to the natural human IFNω in vitro. HIS agonists induced comparable levels of the antiviral genes as natural human IFNω but minimal expression of pro-inflammatory genes. VHH single variable domain of a heavy-chain, scFv single chain antibody fragment
See this image and copyright information in PMC

Comment on

  • Facile discovery of surrogate cytokine agonists.
    Yen M, Ren J, Liu Q, Glassman CR, Sheahan TP, Picton LK, Moreira FR, Rustagi A, Jude KM, Zhao X, Blish CA, Baric RS, Su LL, Garcia KC. Yen M, et al. Cell. 2022 Apr 14;185(8):1414-1430.e19. doi: 10.1016/j.cell.2022.02.025. Epub 2022 Mar 23. Cell. 2022. PMID: 35325595 Free PMC article.

References

    1. Yen M, et al. Facile discovery of surrogate cytokine agonists. Cell. 2022;185:1414–1430.e19. doi: 10.1016/j.cell.2022.02.025. - DOI - PMC - PubMed
    1. Yan W, et al. Structural biology of SARS-CoV-2: open the door for novel therapies. Signal Transduct. Target Ther. 2022;7:26. doi: 10.1038/s41392-022-00884-5. - DOI - PMC - PubMed
    1. Paludan SR, Mogensen TH. Innate immunological pathways in COVID-19 pathogenesis. Sci. Immunol. 2022;7:eabm5505. doi: 10.1126/sciimmunol.abm5505. - DOI - PubMed
    1. Andreakos E. STINGing type I IFN-mediated immunopathology in COVID-19. Nat Immunol. 2022;23:478–480. doi: 10.1038/s41590-022-01174-6. - DOI - PubMed
    1. Glassman CR, et al. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science. 2022;376:eabn8933. doi: 10.1126/science.abn8933. - DOI - PMC - PubMed

Publication types